Paper36912188
Characterization of immune cell populations in syngeneic murine tumor models.
Snipstad S and 3 others. Cancer Med, 2023. Cited by 20 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Characterization of immune cell populations in syngeneic murine tumor models. Papers, record 36912188. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36912188
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| T-Lymphocytes | Major topic |
| Colonic Neoplasms | Major topic |
| Animals | |
| Mice | |
| Tumor Microenvironment | |
| Cell Line, Tumor | |
| Immunotherapy | |
| Disease Models, Animal |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28,819,064 | The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. | Cancer Immunol Res | 2017 | https://conductscience.org/library/papers/28819064 | PubMed |
| 2 | 36,912,188 | Characterization of immune cell populations in syngeneic murine tumor models. | Cancer Med | 2023 | https://conductscience.org/library/papers/36912188 | PubMed |
| 3 | 24,277,834 | Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/24277834 | PubMed |
| 4 | 18,432,775 | Mouse 4T1 breast tumor model. | Curr Protoc Immunol | 2001 | https://conductscience.org/library/papers/18432775 | PubMed |
| 5 | 25,979,873 | Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. | Cancer Res | 2015 | https://conductscience.org/library/papers/25979873 | PubMed |
| 6 | 27,248,578 | Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. | Curr Protoc Pharmacol | 2016 | https://conductscience.org/library/papers/27248578 | PubMed |
| 7 | 32,179,637 | Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. | J Immunol | 2020 | https://conductscience.org/library/papers/32179637 | PubMed |
| 8 | 29,684,498 | Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models. | J Control Release | 2018 | https://conductscience.org/library/papers/29684498 | PubMed |
| 9 | 30,610,226 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/30610226 | PubMed |
| 10 | 30,356,816 | The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. | Front Immunol | 2018 | https://conductscience.org/library/papers/30356816 | PubMed |
| 11 | 25,888,329 | Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25888329 | PubMed |
| 12 | 1,255,804 | Murine colon adenocarcinomas: methods for selective culture in vitro. | J Natl Cancer Inst | 1976 | https://conductscience.org/library/papers/1255804 | PubMed |
| 13 | 30,309,862 | Mouse Models for Cancer Immunotherapy Research. | Cancer Discov | 2018 | https://conductscience.org/library/papers/30309862 | PubMed |
| 14 | 28,302,645 | PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. | J Exp Med | 2017 | https://conductscience.org/library/papers/28302645 | PubMed |
| 15 | 31,779,705 | Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31779705 | PubMed |
| 16 | 30,388,137 | Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. | PLoS One | 2018 | https://conductscience.org/library/papers/30388137 | PubMed |
| 17 | 12,946,314 | Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. | Mol Ther | 2003 | https://conductscience.org/library/papers/12946314 | PubMed |
| 18 | 24,991,577 | The roles of regulatory B cells in cancer. | J Immunol Res | 2014 | https://conductscience.org/library/papers/24991577 | PubMed |
| 19 | 31,200,747 | B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31200747 | PubMed |
| 20 | 28,569,770 | Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. | Cell Death Dis | 2017 | https://conductscience.org/library/papers/28569770 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,564,443 | A low-dose immunotherapy targeting Fc gamma Receptors and heparan sulfate proteoglycan to impact myeloid cells and control cancers with diverse immunosuppressive profiles. | Front Immunol | 2026 | https://conductscience.org/library/papers/42564443 | PubMed |
| 42,251,180 | The electrical and chemical hypoxia-optimized (ECHO) bioreactor system enables scalable production of functionally preserved NK-exosomes validated in a syngeneic lung cancer model. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42251180 | PubMed |
| 42,162,232 | Tumor implantation site dictates the immune landscape of syngeneic mouse models of head and neck cancer. | Sci Rep | 2026 | https://conductscience.org/library/papers/42162232 | PubMed |
| 41,961,275 | Challenges in tracer development for tumor microenvironment (TME) imaging. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/41961275 | PubMed |
| 41,624,403 | Virus-based IFNγ gene delivery and photodynamic therapy cooperate to remodel the tumor microenvironment and suppress breast cancer. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41624403 | PubMed |
| 41,322,421 | Single-cell atlas of the tumor immune microenvironment across syngeneic murine models. | Front Immunol | 2025 | https://conductscience.org/library/papers/41322421 | PubMed |
| 41,205,593 | Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/41205593 | PubMed |
| 41,148,819 | The Immunomodulatory Role of Gemcitabine in Triple Negative Breast Cancer. | Cells | 2025 | https://conductscience.org/library/papers/41148819 | PubMed |
| 41,130,795 | PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model. | J Nucl Med | 2025 | https://conductscience.org/library/papers/41130795 | PubMed |
| 40,707,495 | The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer. | NPJ Breast Cancer | 2025 | https://conductscience.org/library/papers/40707495 | PubMed |
| 40,403,728 | Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. | Cell | 2025 | https://conductscience.org/library/papers/40403728 | PubMed |
| 40,026,631 | Lymph node-targeted delivery of Lonicera japonica thunb. polysaccharides for enhancing antitumor immunotherapy. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40026631 | PubMed |
| 39,708,807 | Inflammation switches the chemoattractant requirements for naive lymphocyte entry into lymph nodes. | Cell | 2025 | https://conductscience.org/library/papers/39708807 | PubMed |
| 39,250,241 | Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer. | Cancer Res | 2024 | https://conductscience.org/library/papers/39250241 | PubMed |
| 38,918,836 | Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models. | Breast Cancer Res | 2024 | https://conductscience.org/library/papers/38918836 | PubMed |
| 38,515,636 | Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines. | BME Front | 2024 | https://conductscience.org/library/papers/38515636 | PubMed |
| 36,912,188 | Characterization of immune cell populations in syngeneic murine tumor models. | Cancer Med | 2023 | https://conductscience.org/library/papers/36912188 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36912188
GET https://conductscience.org/api/papers/v1/36912188/references?page=2